What is Acro Biotech?
Acro Biotech, Inc. operates as a specialized provider of rapid diagnostic solutions, catering to a diverse array of clinical needs. The company's portfolio encompasses critical testing categories, including infectious diseases, women's health, tumor markers, and cardiac diagnostics. Beyond human healthcare, the firm has diversified its reach into veterinary applications and diagnostic instrumentation, such as urine analyzers and glucose monitoring systems. By focusing on high-throughput, reliable testing platforms, Acro Biotech serves as a vital partner for laboratories and healthcare providers seeking to optimize diagnostic workflows. While the company maintains a broad international footprint, its strategic focus remains on delivering accessible and efficient testing tools that address evolving public health requirements.
How much funding has Acro Biotech raised?
Acro Biotech has raised a total of $32K across 1 funding round:
Debt
$32K
Debt (2021): $32K with participation from PPP
Key Investors in Acro Biotech
PPP
Public-Private Partnership
What's next for Acro Biotech?
With the successful completion of this Series B/C stage financing, Acro Biotech is poised to accelerate its strategic roadmap. The infusion of capital will likely be directed toward expanding manufacturing capacity and refining its diagnostic pipeline to meet increasing global demand for rapid testing. As the company navigates the complexities of the biotechnology market, management will likely prioritize regulatory compliance and the integration of advanced analytical technologies to maintain its market share. Future growth will depend on the firm's ability to scale its infrastructure while maintaining the rigorous quality standards required by clinical laboratories and healthcare institutions worldwide. The company remains a key player to watch as it transitions into its next phase of operational maturity.
See full Acro Biotech company page
